Your shopping cart is empty.

ACENOpgx

Pharmacogenetics DNA test for acenocoumarol
Appropriate response to acenocoumarol treatment.
Adequate response to treatment with acenocoumarol or warfarin. This DNA test analyzes polymorphisms of genes that provide insight into the initial dose of acenocoumarol (Sintrom®) or warfarin (Coumadin®), required in order to prevent b...
Adequate response to treatment with acenocoumarol or warfarin. This DNA test analyzes polymorphisms of genes that provide insight into the initial dose of acenocoumarol (Sintrom®) or warfarin (Coumadin®), required in order to prevent bleeding. Indicated in patients who are within the first 6 months of starting the treatment.
175,00

Sample type:

Saliva

Delivery period:

30 - 40 days from sample receipt.
Last update of the document Jun, 10/06/2019 - 13:05

Acenocumarol (Sintrom®) DNA test

In Spain, acenocoumarol (Sintrom®) is consumed by more than 600,000 people, or warfarin (in the USA), are two similar drugs used to prevent the formation of thrombi in people with cardiovascular diseases. In Spain, for commercial reasons, acenocoumarol (Sintrom®) has had more implantation, but from a genetic and interaction point of view they have the same behavior, although the doses are different. (Warfarin dose / 2 = Sintrom® dose)

The main problem is the difficulty of customizing the initial dose and 20% of people present a risk of hemorrhage within the first six months.

The elimination of the drug is done by the liver enzyme CYP2C9 that depends on the CYP2C9 gene. There are mutations of this gene whose consequence is to encode the synthesis of an enzyme with less or almost no activity, so that people who have an alteration in this gene, the doses considered "normal" or habitual, will produce an accumulation of the medication, with a high risk of bleeding.

The FDA-USA obliges to put in the warfarin brochures that "it is recommended to study the polymorphisms of the CYP2C9 and VKORC1 genes to adjust the initial dose ...".

There are many medications and lifestyle habits that induce or inhibit the enzymes involved in the metabolism and action of acenocoumarol.

The calculation of the dose according to the patient's genes is the starting point, but all the medication used and the consumption of nutritional supplements or medicinal herbs

Although controls are already made on the blood coagulation index to control the dose. If from the beginning, the right dose is given for each person, much fewer controls will be needed and patients will have much less risk of bleeding.

Important studies show that if the patient's genes are studied at the beginning of the treatment, and based on them the initial dose is calculated according to the algorithm of The International Warfarin Pharmacogenetics Consortium, the risk of hemorrhaging drops significantly.

Interpretation of the report in Polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

 

 

 

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Info producto mobile

Profile Information

Acenocumarol (Sintrom®) DNA test

In Spain, acenocoumarol (Sintrom®) is consumed by more than 600,000 people, or warfarin (in the USA), are two similar drugs used to prevent the formation of thrombi in people with cardiovascular diseases. In Spain, for commercial reasons, acenocoumarol (Sintrom®) has had more implantation, but from a genetic and interaction point of view they have the same behavior, although the doses are different. (Warfarin dose / 2 = Sintrom® dose)

The main problem is the difficulty of customizing the initial dose and 20% of people present a risk of hemorrhage within the first six months.

The elimination of the drug is done by the liver enzyme CYP2C9 that depends on the CYP2C9 gene. There are mutations of this gene whose consequence is to encode the synthesis of an enzyme with less or almost no activity, so that people who have an alteration in this gene, the doses considered "normal" or habitual, will produce an accumulation of the medication, with a high risk of bleeding.

The FDA-USA obliges to put in the warfarin brochures that "it is recommended to study the polymorphisms of the CYP2C9 and VKORC1 genes to adjust the initial dose ...".

There are many medications and lifestyle habits that induce or inhibit the enzymes involved in the metabolism and action of acenocoumarol.

The calculation of the dose according to the patient's genes is the starting point, but all the medication used and the consumption of nutritional supplements or medicinal herbs

Although controls are already made on the blood coagulation index to control the dose. If from the beginning, the right dose is given for each person, much fewer controls will be needed and patients will have much less risk of bleeding.

Important studies show that if the patient's genes are studied at the beginning of the treatment, and based on them the initial dose is calculated according to the algorithm of The International Warfarin Pharmacogenetics Consortium, the risk of hemorrhaging drops significantly.

Interpretation of the report in Polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

 

 

 

Sample type and process to follow

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Documentación